| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 1,302,115 | 1,096,830 | 1,032,096 | 700,202 |
| Costs of sales | 452,388 | 408,461 | 406,721 | 159,350 |
| Gross profit | 849,727 | 688,369 | 625,375 | 540,852 |
| Selling, general and administrative | 1,296,193 | 1,267,707 | 1,165,517 | 1,192,874 |
| Total operating expenses | 1,296,193 | 1,267,707 | 1,165,517 | 1,192,874 |
| Loss from operations | -446,466 | -579,338 | -540,142 | -652,022 |
| Interest income (expense), net | -175,282 | -771 | 409 | 1,153 |
| Gain on settlement of legacy accounts payable obligations | NaN | 0 | NaN | NaN |
| Other income | 3,282 | 1,629 | 1,814 | 1,180 |
| Loss before benefit for income taxes | NaN | -578,480 | NaN | NaN |
| Total other income (expenses) | -172,000 | NaN | 2,223 | 2,333 |
| Net loss | -618,466 | -578,480 | -537,919 | -649,689 |
| Basic EPS | -0.01 | -0.012 | -0.01 | -0.01 |
| Basic Average Shares | 48,285,303 | 48,072,299 | 47,539,384 | 46,823,111 |
Nuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc. (AURX)